tailieunhanh - Báo cáo y học: " Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học 'Respiratory Research cung cấp cho các bạn kiến thức về ngành y đề tài: Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations. | VanDevanter et al. Respiratory Research 2010 11 137 http content 11 1 137 RESPIRATORY RESEARCH RESEARCH Open Access Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations Donald R VanDevanter1 Mary A O Riordan1 2 Jeffrey L Blumer1 2 Michael W Konstan1 2 Abstract Background Cystic Fibrosis CF is a life-shortening genetic disease in which 80 of deaths result from loss of lung function linked to inflammation due to chronic bacterial infection principally Pseudomonas aeruginosa . Pulmonary exacerbations intermittent episodes during which symptoms of lung infection increase and lung function decreases can cause substantial resource utilization morbidity and irreversible loss of lung function. Intravenous antibiotic treatment to reduce exacerbation symptoms is standard management practice. However no prospective studies have identified an optimal antibiotic treatment duration and this lack of objective data has been identified as an area of concern and interest. Methods We have retrospectively analyzed pulmonary function response data as forced expiratory volume in one second FEV1 from a previous blinded controlled CF exacerbation management study of intravenous ceftazidime tobramycin and meropenem tobramycin in which spirometry was conducted daily to assess the time course of pulmonary function response. Results Ninety-five patients in the study received antibiotics for at least 4 days and were included in our analyses. Patients received antibiotics for an average of days median 13 SD days with a range of 4 to 27 days. No significant differences were observed in mean or median treatment durations as functions of either treatment group or baseline lung disease stage. Average time from initiation of antibiotic treatment to highest observed FEV1 was days median 10 SD days with a range of zero to 19 days. Patients were treated an average of days beyond the day of peak .

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN
crossorigin="anonymous">
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.